Paper Details

  1. Home
  2. Paper Details

Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors.

Author: HidaToyoaki, KatoTerufumi, NishioMakoto, ToyozawaRyo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study discusses the use of small molecule mesenchymal-epithelial transition (MET) inhibitors, such as crizotinib, capmatinib, and tepotinib, for metastatic non-small cell lung cancer (NSCLC). The study found that MET inhibitors were associated with a high incidence of peripheral edema, although generally mild-to-moderate in severity. The mechanism involved in MET inhibitor-induced peripheral edema is unknown, but potential mechanisms include perturbation of hepatocyte growth factor (HGF)/MET signaling or effects on renal function.
Paper Details　
Original Abstract of the Article :
Small molecule mesenchymal-epithelial transition (MET) inhibitors, such as crizotinib, capmatinib, and tepotinib, are treatment options for metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumors have a mutation that leads to MET exon 14 skipping. In clinical trials, these MET i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512730/

データ提供：米国国立医学図書館（NLM）

Managing Peripheral Edema in MET Exon 14-Mutated NSCLC: A Balancing Act of Treatment and Side Effects

The battle against non-small cell lung cancer (NSCLC) is complex, with researchers constantly seeking new and effective treatment options. This study focuses on the management of peripheral edema, a common side effect associated with small molecule mesenchymal-epithelial transition (MET) inhibitors used in the treatment of MET exon 14-mutated NSCLC. The authors examine the potential mechanisms behind MET inhibitor-induced peripheral edema and explore various approaches to managing this side effect.

Navigating the Desert of Side Effects

The study reveals that peripheral edema is a frequent side effect of MET inhibitors. While the exact mechanisms are still being explored, the authors discuss potential pathways involving hepatocyte growth factor (HGF)/MET signaling and renal function. This knowledge is crucial for clinicians to understand and manage this side effect effectively. The study emphasizes the importance of early diagnosis and treatment of peripheral edema, along with patient education and monitoring, to ensure optimal treatment adherence and minimize the clinical burden associated with this side effect.

Navigating the Desert of Side Effects

This research sheds light on the delicate balance between effective cancer treatment and managing its side effects. The study highlights the importance of comprehensive patient care, including thorough assessments, preventative measures, and individualized management strategies for peripheral edema. This research serves as a roadmap for clinicians to navigate the desert of side effects and provide the best possible care for patients undergoing treatment with MET inhibitors.

Dr. Camel's Conclusion

Navigating the landscape of NSCLC treatment can be like traversing a vast desert, full of challenges and unexpected obstacles. This study helps clinicians understand the potential side effects of MET inhibitors, particularly peripheral edema, and emphasizes the importance of careful monitoring and individualized management strategies to ensure the best possible outcome for patients.

Date :
  1. Date Completed 2022-09-28
  2. Date Revised 2022-10-13
Further Info :

Pubmed ID

36087188

DOI: Digital Object Identifier

PMC9512730

Related Literature

Article Analysis
・Effects of capmatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.